Company Overview of Intersect ENT, Inc.
Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The company is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting; and NOVA, a steroid releasing implant to fit the ostia, or openings, of the dependent sinuses following enlargement of the sinuses. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, I...
1555 Adams Drive
Menlo Park, CA 94025
Founded in 2003
Key Executives for Intersect ENT, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $442.4K
Chief Financial Officer
Total Annual Compensation: $357.9K
Chief Operating Officer and Vice President of R&D & Operations
Total Annual Compensation: $324.1K
Vice President of Clinical Affairs
Total Annual Compensation: $263.7K
Compensation as of Fiscal Year 2015.
Intersect ENT, Inc. Key Developments
Intersect ENT, Inc. Maintains Revenue Guidance for the Year 2017
Feb 24 17
Intersect ENT, Inc. company maintained its previously stated 2017 revenue guidance of $87 million to $89 million.
Intersect ENT, Inc. Wins FDA Approval of Newest Steroid Releasing Implant, PROPEL Contour, for Use in Treating the Frontal and Maxillary Sinuses
Feb 24 17
Intersect ENT, Inc. announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for its PROPELÂ® Contour steroid releasing sinus implant. PROPEL Contour features an innovative hourglass design that facilitates treatment of patients with chronic sinusitis in the frontal (behind the forehead) and maxillary (behind the cheeks) sinuses. With this approval, Intersect ENT's PROPEL family of steroid releasing implants allows for treatment of patients undergoing ethmoid, frontal or maxillary surgeries, which represent the majority of procedures for the treatment of chronic sinusitis. PROPEL Contour, the latest in the PROPEL family of steroid releasing sinus implants, is specifically designed to conform to the sinus ostia (openings), focusing drug delivery and mechanical support where it is needed in order to maximize sinus surgery outcomes. The implant features a low-profile flexible delivery system to make it easier to access tight areas of the sinus anatomy. Positive data from the PROPEL Contour cohort of the PROGRESS study, a prospective, randomized, blinded, multi-center trial of 80 patients designed to assess the safety and efficacy of the implant when placed in the frontal sinuses following surgery, supported the approval. The study met its primary efficacy endpoint, demonstrating a statistically significant 65% relative reduction in the need for post-operative interventions, such as the need for additional surgical procedures or the need for oral steroid prescription, compared to surgery alone.
Intersect ENT, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 10:30 AM
Jan 24 17
Intersect ENT, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 10:30 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|